中国临床药理学杂志2025，Vol.41Issue(10)：1362-1366,5.DOI:10.13699/j.cnki.1001-6821.2025.10.003
古塞奇尤单抗联合NB-UVB治疗寻常性银屑病患者的临床研究
Clinical trial of gusetuximab combined with NB-UVB in the treatment of patients with psoriasis vulgaris
摘要
Abstract
Objective To observe the clinical efficacy and safety of gusechiumab injection combined with narrow bound ultra violet B(NB-UVB)in the treatment of patients with psoriasis vulgaris.Methods The patients with psoriasis vulgaris were divided into control group and treatment group according to cohort method.The control group received NB-UVB treatment,the initial irradiation dose was 0.3-0.5 J·cm-2,and each irradiation dose was increased by 10％-20％on the basis of the previous irradiation,and the maximum daily dose was＜3.5 J·cm-2 for 24 weeks.On the basis of the control group,the treatment group was combined with gusechiumab 100 mg each time by subcutaneous injection,administered once each in weeks 0 and 4,and then once every 8 weeks thereafter,for 24 weeks.The clinical efficacy,inflammatory response,quality of life,psoriasis area and severity index(PASI)score and safety of the two groups were compared.Results There were 72 patients in the treatment group and 73 in the control group.After treatment,the total effective rates of treatment group and control group were 97.22％(70 cases/72 cases)and 86.30％ (63 cases/73 cases),and the difference was statistically significant(P＜0.05).After treatment,the levels of interleukin-23(IL-23)in treatment group and control group were(128.14±14.20)and(145.21±16.33)ng·L-1;the levels of IL-17 were(62.07±7.11)and(75.29±8.36)ng·L-1;the levels of tumor necrosis factor-α were(29.73±4.16)and(35.25±5.61)ng·L-1;the skin disease life quality index(DLQI)scores were(7.01±1.33)and(9.35±1.98)points;the PASI scores were(4.02±1.17)and(6.19±1.53)points,respectively;the differences of above indexes between two groups were statistically significant(all P＜0.05).The adverse drug reactions of the treatment group mainly included respiratory tract infection,injection site reaction and skin pain,while the adverse drug reactions of the control group mainly included skin pain and pruritus.The total incidences of adverse drug reactions in treatment group and control group were 6.94％and 4.11％,respectively,without statistical significance(P＞0.05).Conclusion Gusechiumab injection combined with NB-UVB has definite clinical efficacy in the treatment of psoriasis vulgaris patients,which can reduce the inflammatory response and skin lesions of patients,improve the quality of life,and without increasing the incidence of adverse drug reactions.关键词
古塞奇尤单抗注射液/窄谱中波紫外线/寻常性银屑病/临床疗效/安全性评价Key words
guselkumab injection/narrow bound ultra violet B/psoriasis vulgaris/clinical efficacy/safety evaluation分类
医药卫生引用本文复制引用
刘贞君,管延美,马树媛,郭锦锦,田涛..古塞奇尤单抗联合NB-UVB治疗寻常性银屑病患者的临床研究[J].中国临床药理学杂志,2025,41(10):1362-1366,5.基金项目
山东省医药卫生科技发展计划基金资助项目(202103020493) （202103020493）
